+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 216 Pages
  • April 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5589922
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Drugs In Development, 2022, provides an overview of the Anal Cancer (Oncology) pipeline landscape.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity.

Report Highlights


The Pharmaceutical and Healthcare latest pipeline guide Anal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 36, 27, 2 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.

Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anal Cancer (Oncology)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

IntroductionReport CoverageAnal Cancer - Overview
Anal Cancer - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Anal Cancer - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Anal Cancer - Companies Involved in Therapeutics DevelopmentAnal Cancer - Drug ProfilesAnal Cancer - Dormant ProjectsAnal Cancer - Discontinued ProductsAnal Cancer - Product Development Milestones
Featured News & Press Releases
  • Dec 06, 2021: PDS Biotech provides recruitment update for National Cancer Institute-Led phase 2 clinical trial of PDS0101-based combination
  • Oct 15, 2021: Zynyz: Withdrawal of the marketing authorisation application
  • Jul 23, 2021: Incyte provides regulatory update on retifanlimab for the treatment of certain patients with squamous cell carcinoma of the anal canal (SCAC)
  • Jun 24, 2021: Incyte announces outcome of FDA Oncologic Drugs Advisory Committee (ODAC) meeting reviewing retifanlimab as a treatment for patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
  • Jun 24, 2021: Transgene: First patient enrolled in expanded phase II clinical trial of TG4001 + avelumab Vs avelumab alone in patients With HPV16-positive anogenital cancers
  • Mar 10, 2021: Transgene expands phase II clinical trial of therapeutic vaccine TG4001 in combination with Avelumab versus Avelumab monotherapy in patients with HPV16-positive anogenital cancers
  • Feb 26, 2021: Incyte announces the validation by the European Medicines Agency of its marketing authorization application for retifanlimab as a treatment for patients with squamous cell anal carcinoma (SCAC)
  • Nov 30, 2020: MacroGenics announces achievement of $25 million in milestones related to retifanlimab collaboration with Incyte
  • Apr 08, 2019: Inovio achieves third cancer indication milestone for MEDI0457 phase 2 development
  • Apr 03, 2019: MacroGenics reports presentation of data on MGA-012 at the AACR Annual Meeting 2019
  • Sep 27, 2018: Vaccine, anti-PD1 drug show promise against incurable HPV-related cancers
  • Sep 11, 2017: Combined Therapy with Nivolumab and ISA 101 Vaccine Results in Promising Efficacy in HPV-positive Oropharyngeal Cancer
  • Nov 08, 2016: Dr. Shepard, CMO Of PDS Biotechnology, To Present PDS0101 Phase I/IIA Clinical Data At The Society For Immunotherapy Of Cancer Meeting On November 11, 2016
  • Jun 05, 2016: Nivolumab shows promise in first-ever trial for patients with refractory, metastatic anal cancer
  • Dec 07, 2015: ISA Pharmaceuticals’ ISA101 Studied in Phase II Combination Trial with Checkpoint Inhibitor Nivolumab
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact the Analyst
List of Tables
  • Number of Products under Development for Anal Cancer, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Anal Cancer - Pipeline by Antiva Biosciences Inc, 2022
  • Anal Cancer - Pipeline by AstraZeneca Plc, 2022
  • Anal Cancer - Pipeline by Beijing Corregene Biotechnology Co Ltd, 2022
  • Anal Cancer - Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, 2022
  • Anal Cancer - Pipeline by Bicara Therapeutics Inc, 2022
  • Anal Cancer - Pipeline by Biomimetix JV LLC, 2022
  • Anal Cancer - Pipeline by Bristol-Myers Squibb Co, 2022
  • Anal Cancer - Pipeline by Cue Biopharma Inc, 2022
  • Anal Cancer - Pipeline by CytomX Therapeutics Inc, 2022
  • Anal Cancer - Pipeline by Eisai Co Ltd, 2022
  • Anal Cancer - Pipeline by Eli Lilly and Co, 2022
  • Anal Cancer - Pipeline by EpimAb Biotherapeutics Inc, 2022
  • Anal Cancer - Pipeline by eTheRNA Immunotherapies NV, 2022
  • Anal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, 2022
  • Anal Cancer - Pipeline by Fujifilm Holdings Corp, 2022
  • Anal Cancer - Pipeline by Genexine Inc, 2022
  • Anal Cancer - Pipeline by Genocea Biosciences Inc, 2022
  • Anal Cancer - Pipeline by Gilead Sciences Inc, 2022
  • Anal Cancer - Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, 2022
  • Anal Cancer - Pipeline by HaloVax, 2022
  • Anal Cancer - Pipeline by Hookipa Pharma Inc, 2022
  • Anal Cancer - Pipeline by IMV Inc, 2022
  • Anal Cancer - Pipeline by Incyte Corp, 2022
  • Anal Cancer - Pipeline by Invectys SA, 2022
  • Anal Cancer - Pipeline by ISA Pharmaceuticals BV, 2022
  • Anal Cancer - Pipeline by Merck & Co Inc, 2022
  • Anal Cancer - Pipeline by Merck KGaA, 2022
  • Anal Cancer - Pipeline by Mereo Biopharma Group Plc, 2022
  • Anal Cancer - Pipeline by Molecular Partners AG, 2022
  • Anal Cancer - Pipeline by Nektar Therapeutics, 2022
  • Anal Cancer - Pipeline by Novartis AG, 2022
  • Anal Cancer - Pipeline by Oncolytics Biotech Inc, 2022
  • Anal Cancer - Pipeline by Onconova Therapeutics Inc, 2022
  • Anal Cancer - Pipeline by Oncorus Inc, 2022
  • Anal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, 2022
  • Anal Cancer - Pipeline by PDS Biotechnology Corp, 2022
  • Anal Cancer - Pipeline by Precigen Inc, 2022
  • Anal Cancer - Pipeline by Privo Technologies Inc, 2022
  • Anal Cancer - Pipeline by Repertoire Immune Medicines Inc, 2022
  • Anal Cancer - Pipeline by Rubius Therapeutics Inc, 2022
  • Anal Cancer - Pipeline by Sanofi, 2022
  • Anal Cancer - Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022
  • Anal Cancer - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
  • Anal Cancer - Pipeline by Shanghai Zerun Biotechnology Co Ltd, 2022
  • Anal Cancer - Pipeline by Shattuck Labs Inc, 2022
  • Anal Cancer - Pipeline by SinoCelltech Group Ltd, 2022
  • Anal Cancer - Pipeline by SOTIO Biotech AS, 2022
  • Anal Cancer - Pipeline by SQZ Biotechnologies Co, 2022
  • Anal Cancer - Pipeline by Statera Biopharma Inc, 2022
  • Anal Cancer - Pipeline by Transgene SA, 2022
  • Anal Cancer - Pipeline by Treadwell Therapeutics Inc, 2022
  • Anal Cancer - Pipeline by TScan Therapeutics Inc, 2022
  • Anal Cancer - Pipeline by Turnstone Biologics Inc, 2022
  • Anal Cancer - Pipeline by Virion Therapeutics LLC, 2022
  • Anal Cancer - Pipeline by Xencor Inc, 2022
  • Anal Cancer - Pipeline by Y-Biologics Inc, 2022
  • Anal Cancer - Pipeline by Zymeworks Inc, 2022
  • Anal Cancer - Dormant Projects, 2022
  • Anal Cancer - Discontinued Products, 2022

List of Figures
  • Number of Products under Development for Anal Cancer, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Top 10 Routes of Administration, 2022
  • Number of Products by Stage and Top 10 Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Antiva Biosciences Inc
  • AstraZeneca Plc
  • Beijing Corregene Biotechnology Co Ltd
  • Beijing Kangle Guardian Biotechnology Co Ltd
  • Bicara Therapeutics Inc
  • Biomimetix JV LLC
  • Bristol-Myers Squibb Co
  • Cue Biopharma Inc
  • CytomX Therapeutics Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • EpimAb Biotherapeutics Inc
  • eTheRNA Immunotherapies NV
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Holdings Corp
  • Genexine Inc
  • Genocea Biosciences Inc
  • Gilead Sciences Inc
  • Guangzhou BeBetter Medicine Technology Co Ltd
  • HaloVax
  • Hookipa Pharma Inc
  • IMV Inc
  • Incyte Corp
  • Invectys SA
  • ISA Pharmaceuticals BV
  • Merck & Co Inc
  • Merck KGaA
  • Mereo Biopharma Group Plc
  • Molecular Partners AG
  • Nektar Therapeutics
  • Novartis AG
  • Oncolytics Biotech Inc
  • Onconova Therapeutics Inc
  • Oncorus Inc
  • Ono Pharmaceutical Co Ltd
  • PDS Biotechnology Corp
  • Precigen Inc
  • Privo Technologies Inc
  • Repertoire Immune Medicines Inc
  • Rubius Therapeutics Inc
  • Sanofi
  • Shanghai De Novo Pharmatech Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Shanghai Zerun Biotechnology Co Ltd
  • Shattuck Labs Inc
  • SinoCelltech Group Ltd
  • SOTIO Biotech AS
  • SQZ Biotechnologies Co
  • Statera Biopharma Inc
  • Transgene SA
  • Treadwell Therapeutics Inc
  • TScan Therapeutics Inc
  • Turnstone Biologics Inc
  • Virion Therapeutics LLC
  • Xencor Inc
  • Y-Biologics Inc
  • Zymeworks Inc